FY2025 Earnings Forecast for TSHA Issued By Chardan Capital

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) – Chardan Capital issued their FY2025 earnings per share estimates for Taysha Gene Therapies in a research report issued on Wednesday, August 13th. Chardan Capital analyst Y. Livshits forecasts that the company will post earnings of ($0.31) per share for the year. Chardan Capital has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Taysha Gene Therapies’ current full-year earnings is ($0.35) per share.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The company had revenue of $1.99 million for the quarter, compared to the consensus estimate of $1.61 million. Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%.

Several other equities research analysts have also commented on TSHA. Citigroup restated an “outperform” rating on shares of Taysha Gene Therapies in a report on Thursday, May 29th. Bank of America began coverage on Taysha Gene Therapies in a research note on Friday, July 11th. They set a “buy” rating and a $8.00 price target on the stock. Canaccord Genuity Group lifted their price objective on Taysha Gene Therapies from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, June 3rd. JMP Securities increased their price target on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a “market outperform” rating in a report on Thursday, May 29th. Finally, Wells Fargo & Company lifted their price target on shares of Taysha Gene Therapies from $7.50 to $8.00 and gave the company an “overweight” rating in a research note on Wednesday, August 13th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies has a consensus rating of “Buy” and an average target price of $8.29.

Taysha Gene Therapies Price Performance

TSHA opened at $2.94 on Monday. The business has a fifty day moving average of $2.60 and a 200 day moving average of $2.12. The company has a quick ratio of 12.48, a current ratio of 12.48 and a debt-to-equity ratio of 0.17. The stock has a market cap of $631.10 million, a P/E ratio of -8.65 and a beta of 0.98. Taysha Gene Therapies has a 52-week low of $1.05 and a 52-week high of $3.31.

Insider Activity

In related news, major shareholder Paul B. Manning acquired 750,000 shares of the firm’s stock in a transaction that occurred on Friday, May 30th. The shares were purchased at an average price of $2.75 per share, with a total value of $2,062,500.00. Following the completion of the acquisition, the insider owned 2,841,704 shares in the company, valued at approximately $7,814,686. This represents a 35.86% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 3.78% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TSHA. Ground Swell Capital LLC acquired a new stake in Taysha Gene Therapies during the fourth quarter worth about $25,000. E Fund Management Co. Ltd. acquired a new stake in Taysha Gene Therapies during the 2nd quarter valued at approximately $31,000. Hsbc Holdings PLC raised its holdings in Taysha Gene Therapies by 65.6% in the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock valued at $36,000 after acquiring an additional 8,076 shares in the last quarter. May Hill Capital LLC bought a new stake in Taysha Gene Therapies in the second quarter valued at about $37,000. Finally, Ameriprise Financial Inc. acquired a new position in Taysha Gene Therapies in the fourth quarter worth $40,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.